<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36005791</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7488</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of nursing</Title><ISOAbbreviation>Am J Nurs</ISOAbbreviation></Journal><ArticleTitle>New Oral Form for ALS Drug.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>25</EndPage><MedlinePgn>24-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/01.NAJ.0000874104.26408.02</ELocationID><Abstract><AbstractText>The Food and Drug Administration has approved an oral suspension form of edaravone (Radicava ORS) for the treatment of amyotrophic lateral sclerosis.Edaravone should be taken on an empty stomach in the morning either by mouth or through a feeding tube. Feeding tubes should be flushed before and after drug administration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aschenbrenner</LastName><ForeName>Diane S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Nurs</MedlineTA><NlmUniqueID>0372646</NlmUniqueID><ISSNLinking>0002-936X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013535">Suspensions</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013535" MajorTopicYN="N">Suspensions</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36005791</ArticleId><ArticleId IdType="doi">10.1097/01.NAJ.0000874104.26408.02</ArticleId><ArticleId IdType="pii">00000446-202209000-00022</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCE</Title><Reference><Citation>Farooq O, Sharma N. Clinical efficacy and safety of edaravone a new molecule as a ray of hope for motor neuron disease (an incurable illness) a mini review. Clinical Case Reports International 2020 May 18. http://www.clinicalcasereportsint.com/open-access/clinical-efficacy-and-safety-of-edaravone-a-new-molecule-as-5911.pdf .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>